The deal is the latest in a series of Sanofi investments in its immunology portfolio. According to Sanfoi, DR-0201 can achieve deep B cell depletion, giving it the potential to reset the immune system.
Sanofi Commits up to $1.9B for Dren Bio’s Bispecific Antibody for Autoimmune Disease